Vol 9, No 3 (2018)
Case report
Published online: 2018-10-17

open access

Page views 939
Article views/downloads 1940
Get Citation

Connect on Social Media

Connect on Social Media

Fluctuating Guillain-Barré syndrome in AL systemic amyloidosis as a progression indicator?

Anna Suska12, Jacek Matyszkiewicz, Artur Jurczyszyn13
Hematologia 2018;9(3):239-244.


Primary systemic light-chain amyloidosis (AL) that accounts for 4/5 of all cases can be manifested as a neuropathy. In some cases, neuropathy is a prodromal symptom, present even before the diagnosis or preceding the progression of the disease. Typically, it is symmetrical and progressive, involving the sensitive rather than motor function in the distal parts of the extremities. It can be accompanied by the paresis and autonomic dysfunction. Some atypical presentations of amyloid neuropathy are also mentioned in the literature including asymmetric polyradiculopathy, cranial nerve (III, V, VII) palsies or multiple mononeuropathies. We present a case study of a 58-year-old male patient with AL kappa-light chain amyloidosis of the kidneys, bone marrow and heart, treated in frontline with VD (bortezmib, dexamethasone) and CyBorD (cyclophosphamide, bortezomib, dexamethasone) and with high-dose melphalan followed by autologous hematopoietic stem cell transplantation (auto-HSCT), who developed Guillain-Barré syndrome not responding to standard treatment (intravenous immunoglobulin and plasmapheresis). Severe symptoms of axonal demyelination proceeded the progression of amyloidosis. The improvement in neurological status was obtained by high dose intravenously corticosteroid therapy. Currently, the patient takes dexamethasone as monotherapy – until now without both hematological and neurological progression. Considering the overall clinical picture, the fluctuating Guillain-Barré syndrome may be a prodromal symptom of the amyloidosis progression.

Article available in PDF format

View PDF (Polish) Download PDF file


  1. Dmoszyńska A, Usnarska-Zubkiewicz L, Walewski J, et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematol Pol. 2017; 48(2): 55–103.
  2. Antoine JC, Camdessanché JP. Paraneoplastic neuropathies. Curr Opin Neurol. 2017; 30(5): 513–520.
  3. Duston MA, Skinner M, Anderson J, et al. Peripheral neuropathy as an early marker of AL amyloidosis. Arch Intern Med. 1989; 149(2): 358–360.
  4. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983; 58(10): 665–683.
  5. Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998; 104(3): 232–237.
  6. Vucic S, Chong PS, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve. 2003; 28(6): 696–702.
  7. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016; 91(9): 947–956.
  8. Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis. 2010; 11(3): 145–157.
  9. Kelly JJ, Kyle RA, O'Brien PC, et al. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979; 6(1): 1–7.
  10. Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol. 2012; 25(5): 564–572.
  11. Barsottini OG, Arantes A, Sigulem D, et al. Axoval neuropathy as initial manifestation of primary amyloidosis: report of a case submitted to bone marrow transplantation. Arq Neuropsiquiatr. 2004; 62(3A): 725–729.
  12. Lingenfelser T, Linke RP, Dette S, et al. AL amyloidosis mimicking a preferentially autonomic chronic Guillain-Barré syndrome. Clin Investig. 1992; 70(2): 159–162.
  13. Kyle RA, Dyck PJ. Amyloidosis and neuropathy. In: Griffin JJ, Low PA. ed. Peripheral neuropathy. WB Saunders Company, Philadelphia 1993: 1294–1310.
  14. Gertz MA, Kyle RA. Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc. 1989; 64(12): 1505–1519.
  15. Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015; 100(10): 1254–1266.
  16. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010; 11(11): 1086–1095.
  17. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012; 26(4): 595–608.

Hematology in Clinical Practice